All In Biotech

Drug Trial Radar · NCT07156201

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years

A First-in-Human, Phase 1a, Randomized, Double-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose and Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Administered Orally to Healthy Adults

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

92

Planned (sponsor's estimate)

Start

Aug 28, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Actio Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Sep 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This first in human trial will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses, multiple ascending doses, and fed and fasted doses of ABS-1230 given orally compared with placebo in adult healthy participants.

Conditions

  • KCNT1-Related Epilepsy

Interventions

  • ABS-1230Drug

    ABS-1230

  • PlaceboDrug

    Placebo

  • OmeprazoleDrug

    Omeprazole

  • VoriconazoleDrug

    Voriconazole

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability (incidence, severity, and dose-relationship of adverse events)Time frame: Measured from Day 1 to End of Study or Early Termination (up to 4 weeks)
  2. Safety and tolerability (incidence, severity, and dose-relationship of clinically significant changes in laboratory parameters)Time frame: Measured from Day 1 to End of Study or Early Termination (up to 4 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Scientia Clinical Research

    Sydney, New South Wales, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.